ClinicalTrials.gg
TerminatedNCT05551273Updated Nov 17, 2026Results posted

Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV

A Phase 2 interventional study of Selgantolimod and Placebo in Hepatitis B and HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Terminated at 12 sites in 4 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by National Institute of Allergy and Infectious Diseases (NIAID) · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
ACTG Network funding disruptions
Updated Nov 17, 2026Now TerminatedResults posted+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
29
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Hepatitis B by National Institute of Allergy and Infectious Diseases (NIAID) — none open to participants now, none under way, none of them phase 3. Hepatitis B · National Institute of Allergy and Infectious Diseases (NIAID).

Enrollment
9th of 13
29 · median 30
Started
2023
the only one that year
Phase 2
6 of 15
none open now
Registered
15th of 15
by date

Among the 15 studies in Hepatitis B by National Institute of Allergy and Infectious Diseases (NIAID), this one is the 9th largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2023, is one of 6 in phase 2, and was the 15th registered.

Hepatitis B

1,048 studies on the registry are indexed under Hepatitis B; 141 are open to participants now.

Browse Hepatitis B studies →

Open to participants now

None of the 15 studies in Hepatitis B by National Institute of Allergy and Infectious Diseases (NIAID) is open now. The open studies under Hepatitis B, anywhere →

Who these studies take

Of the 80 Hepatitis B studies recruiting now, 40 (50%) set no upper age limit and 35 (44%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies in Hepatitis B by National Institute of Allergy and Infectious Diseases (NIAID) as a file.
02

Study summary

The study aimed to assess safety and tolerability of oral toll-like receptor (TLR) 8 agonist Selgantolimod (SLGN) administered for 24 weeks in participants with both chronic hepatitis B (CHB) and HIV who had received suppressive antiviral therapy for both viruses for ≥5 years and have qHBsAg level >1000 (3 log10) IU/mL at screening. The study also evaluated if TLR8 stimulation with SLGN will reduce hepatitis B surface antigen (HBsAg) titers in the blood.

The primary hypotheses of this study were:

  1. Administration of the oral TLR8 agonist SLGN will be safe and well-tolerated in participants with both CHB and HIV on suppressive antiviral therapy for both viruses.
  2. TLR8 stimulation with SLGN will reduce HBsAg titers in the blood of participants with both CHB and HIV on suppressive antiviral therapy for both viruses.
Read the detailed description

A5394 was a phase II, randomized, double-blind, placebo-controlled clinical trial to assess the safety, tolerability, and efficacy of 24 weeks of treatment with SLGN. Participants were randomized in a 3:1 ratio to receive SLGN or its placebo, and randomization was stratified by HBeAg status. Participants were planned to be on study for up to 48 weeks (24-week treatment phase and 24-week post-treatment follow-up). All participants were required to remain on their non-study-provided antiviral therapy throughout the study.

The primary efficacy analysis was planned to be conducted as a single-arm study of the SLGN study arm.

Accrual was terminated early and did not reach the target sample size of 48 due to ACTG Network funding disruptions.

03

Conditions studied

  • Hepatitis B
  • HIV Infections
04

Who can participate

The criteria were revised on the registry on Nov 17, 2026. See what changed

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. -1 infection
  2. Effective antiviral therapy for HIV (ART) and that includes TDF, TAF, TDF/FTC, TDF/3TC (tenofovir disoproxil fumarate plus lamivudine), TAF/FTC, or entecavir (ETV), for ≥5 years immediately prior to study entry. ART is defined as including a minimum of two anti-HIV antivirals.
  3. ≥350 cells/mm3
  4. HIV-1 RNA \<50 copies/mL measured on at least two occasions at least 12 weeks apart, with no documented value >200 copies/mL, over the 12 months prior to study entry.
  5. Positive or negative HBeAg
  6. Negative anti-HDV
  7. Current CHB infection
  8. HBV DNA level \<50 IU/mL measured on at least two occasions at least 12 weeks apart, with no documented value ≥50 IU/mL, over the 12 months prior to study entry.
  9. Quantitative HBsAg >1000 IU/mL
  10. virus (HCV) antibody negative, or if the participant is HCV antibody positive, an undetectable HCV RNA.
  11. Participants must agree to stay on an effective antiviral therapy for HIV (ART) and HBV throughout the study.

Exclusion criteria

Exclusion Criteria:

  1. Receipt of treatment for within 24 weeks prior to study entry
  2. Evidence of advanced fibrosis or cirrhosis (Metavir ≥F3 or equivalent).
  3. Current or prior history of clinical hepatic decompensation (e.g., ascites, encephalopathy, or variceal hemorrhage)
  4. History of HCC or cholangiocarcinoma
  5. within 5 years prior to study entry. NOTE: A history of non-melanoma skin cancer (e.g., basal cell carcinoma or squamous cell skin cancer) is not exclusionary.
  6. History of solid organ transplantation
  7. Presence of any active or acute AIDS-defining opportunistic infections within 60 days prior to study entry
  8. History of uveitis or posterior synechiae
  9. Breastfeeding
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    Arm A

    Participants received Selgantolimod 3 mg (two 1.5 mg tablets) once weekly for 24 weeks.

    Drug: Selgantolimod

  • Placebo comparator
    Arm B

    Participants received matching Placebo for Selgantolimod once weekly for 24 weeks.

    Drug: Placebo

Interventions

  • Two 1.5 mg tablets taken orally once a week

    Also known as: SLGN

  • DrugPlacebo

    Two matching placebo tablets taken orally once a week

06

What researchers measure

Primary outcomes

  1. Proportion of Participants Who Experienced Grade ≥2 Adverse Events (AEs) in Arm A

    An adverse event (AE) is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or diagnosis that occurs in a study participant during the conduct of the study REGARDLESS of the attribution. This includes any occurrence that is new in onset or aggravated in severity or frequency from the baseline condition. All AEs that are reported must have their severity graded. Adverse events were graded according to the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), corrected Version 2.1, July 2017. Adverse events were graded on a scale from 1-5: 1=mild, 2=moderate, 3=severe, 4=life-threatening, 5=death. Higher scores/grades mean a worse outcome. The proportion of participants with Grade 2 or higher adverse events was calculated, along with a two-sided 95% confidence interval constructed using the Clopper-Pearson exact method for binomial data.

    Time frame: From study treatment initiation through Week 24

  2. Proportion of Participants Who Prematurely Discontinued Treatment Due to Adverse Events (AEs) in Arm A

    The proportion of participants who had premature discontinuation of Selgantolimod due to adverse event(s) was calculated, along with a two-sided 95% confidence interval constructed using the Clopper-Pearson exact method for binomial data.

    Time frame: From study treatment initiation through Week 24

  3. Proportion of Participants With ≥1 log10 IU/mL Decline From Baseline in Quantitative HBsAg (qHBsAg) After SLGN Treatment at Week 24

    The proportion of participants who experienced ≥1 log10 IU/mL decline in quantitative HBsAg at Week 24 was calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data.

    Time frame: Week 24

Secondary outcomes

  1. Proportion of Participants With ≥1 log10 IU/mL Decline From Baseline in qHBsAg at Any Time During the Study After SLGN Treatment Initiation

    The proportion of participants who experienced ≥1 log10 IU/mL decline in quantitative HBsAg at any time during the study after SLGN treatment initiation will be calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data.

    Time frame: From Baseline (Entry) through Week 48

  2. Proportion of Participants With ≥0.5 log10 IU/mL Decline From Baseline in qHBsAg After SLGN Treatment at Week 24

    The proportion of participants who experienced ≥0.5 log10 IU/mL decline in quantitative HBsAg at Week 24 was calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data.

    Time frame: Week 24

  3. Proportion of Participants With ≥0.5 log10 IU/mL Decline in qHBsAg From Baseline at Any Time During the Study After SLGN Treatment Initiation

    The proportion of participants who experienced ≥0.5 log10 IU/mL decline in quantitative HBsAg at any time during the study after SLGN treatment initiation will be calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data.

    Time frame: From Baseline (Entry) through Week 48

  4. Proportion of Participants Who Achieve HBsAg Loss After SLGN Initiation and Who Sustain HBsAg Loss During Follow-up

    Sustained HBsAg loss is defined as HBsAg converting from positive to negative after initiation of SLGN, without any subsequent positive HBsAg result. The proportion of participants who achieved HBsAg loss after SLGN initiation and who sustained HBsAg loss during follow-up will be calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data.

    Time frame: From Baseline (Entry) through Week 48

  5. Changes From Baseline in qHBsAg Levels

    The absolute change in qHBsAg level refers to the value at the follow-up time point minus the value at Baseline (Entry).

    Time frame: Baseline (Entry) and Weeks 4, 12, 24, 36 and 48

  6. Proportion of Hepatitis B E-antigen (HBeAg) Positive Participants at Baseline Who Lose HBeAg at Any Time During the Study

    HBeAg loss is defined as HBeAg changing from positive to negative. The proportion of participants who lose HBeAg at any time during the study will be calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data.

    Time frame: From Baseline (Entry) through Week 48

  7. Proportion of Hepatitis B E-antibody (Anti-HBe) Negative Participants at Baseline Who Develop Anti-HBe at Any Time During the Study

    Developing anti-HBe, or anti-HBe gain, is defined as HBeAb changing from negative to positive. The proportion of participants who develop HBeAb at any time during the study will be calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data.

    Time frame: From Baseline (Entry) through Week 48

  8. Proportion of Hepatitis B Surface Antibody (Anti-HBs) Negative Participants at Baseline Who Develop Anti-HBs at Any Time During the Study

    Developing anti-HBs, or anti-HBs gain, is defined as HBsAb changing from negative to positive. The proportion of participants who develop HBsAb at any time during the study will be calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data.

    Time frame: From Baseline (Entry) through Week 48

  9. Number of Participants With Plasma HIV RNA >50 Copies/mL

    The number of participants with detectable plasma HIV RNA \>50 copies/mL will be reported.

    Time frame: Weeks 2, 4, 24 and 48

  10. Number of Participants With Serum HBV DNA >50 IU/mL

    The number of participants with detectable serum HBV DNA \>50 copies/mL will be reported.

    Time frame: Weeks 2, 4, 24 and 48

07

Results

Posted Nov 17, 2026
Limitations and caveats
Early termination resulted in a smaller number of participants being analyzed. Although the target sample size was 48 participants, only 29 participants were enrolled, limiting the statistical power of the study.

Participant flow

Participants enrolled during the recruitment period of May 2023 to May 2025 from 12 sites based in the United States, Thailand, Peru, and Brazil.

Participant flow — Overall Study
MilestoneArm AArm B
Started227
Completed207
Not completed20
Withdrew: Withdrawal by subject20

Outcome measures

PrimaryProportion of Participants Who Experienced Grade ≥2 Adverse Events (AEs) in Arm A

An adverse event (AE) is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or diagnosis that occurs in a study participant during the conduct of the study REGARDLESS of the attribution. This includes any occurrence that is new in onset or aggravated in severity or frequency from the baseline condition. All AEs that are reported must have their severity graded. Adverse events were graded according to the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), corrected Version 2.1, July 2017. Adverse events were graded on a scale from 1-5: 1=mild, 2=moderate, 3=severe, 4=life-threatening, 5=death. Higher scores/grades mean a worse outcome. The proportion of participants with Grade 2 or higher adverse events was calculated, along with a two-sided 95% confidence interval constructed using the Clopper-Pearson exact method for binomial data.

Time frame:
From study treatment initiation through Week 24
Reported as:
Number · proportion of participants
Proportion of Participants Who Experienced Grade ≥2 Adverse Events (AEs) in Arm A
proportion of participantsArm A
Proportion of Participants Who Experienced Grade ≥2 Adverse Events (AEs) in Arm A0.727 (0.498 to 0.893)
PrimaryProportion of Participants Who Prematurely Discontinued Treatment Due to Adverse Events (AEs) in Arm A

The proportion of participants who had premature discontinuation of Selgantolimod due to adverse event(s) was calculated, along with a two-sided 95% confidence interval constructed using the Clopper-Pearson exact method for binomial data.

Time frame:
From study treatment initiation through Week 24
Reported as:
Number · proportion of participants
Proportion of Participants Who Prematurely Discontinued Treatment Due to Adverse Events (AEs) in Arm A
proportion of participantsArm A
Proportion of Participants Who Prematurely Discontinued Treatment Due to Adverse Events (AEs) in Arm A0.045 (0.001 to 0.228)
PrimaryProportion of Participants With ≥1 log10 IU/mL Decline From Baseline in Quantitative HBsAg (qHBsAg) After SLGN Treatment at Week 24

The proportion of participants who experienced ≥1 log10 IU/mL decline in quantitative HBsAg at Week 24 was calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data.

Time frame:
Week 24
Reported as:
Number · proportion of participants
Proportion of Participants With ≥1 log10 IU/mL Decline From Baseline in Quantitative HBsAg (qHBsAg) After SLGN Treatment at Week 24
proportion of participantsArm A
Proportion of Participants With ≥1 log10 IU/mL Decline From Baseline in Quantitative HBsAg (qHBsAg) After SLGN Treatment at Week 240.050 (0.003 to 0.216)
SecondaryProportion of Participants With ≥1 log10 IU/mL Decline From Baseline in qHBsAg at Any Time During the Study After SLGN Treatment Initiation

The proportion of participants who experienced ≥1 log10 IU/mL decline in quantitative HBsAg at any time during the study after SLGN treatment initiation will be calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data.

Time frame:
From Baseline (Entry) through Week 48

Results for this outcome have not been posted.

SecondaryProportion of Participants With ≥0.5 log10 IU/mL Decline From Baseline in qHBsAg After SLGN Treatment at Week 24

The proportion of participants who experienced ≥0.5 log10 IU/mL decline in quantitative HBsAg at Week 24 was calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data.

Time frame:
Week 24
Reported as:
Number · proportion of participants
Proportion of Participants With ≥0.5 log10 IU/mL Decline From Baseline in qHBsAg After SLGN Treatment at Week 24
proportion of participantsArm A
Proportion of Participants With ≥0.5 log10 IU/mL Decline From Baseline in qHBsAg After SLGN Treatment at Week 240.050 (0.003 to 0.216)
SecondaryProportion of Participants With ≥0.5 log10 IU/mL Decline in qHBsAg From Baseline at Any Time During the Study After SLGN Treatment Initiation

The proportion of participants who experienced ≥0.5 log10 IU/mL decline in quantitative HBsAg at any time during the study after SLGN treatment initiation will be calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data.

Time frame:
From Baseline (Entry) through Week 48

Results for this outcome have not been posted.

SecondaryProportion of Participants Who Achieve HBsAg Loss After SLGN Initiation and Who Sustain HBsAg Loss During Follow-up

Sustained HBsAg loss is defined as HBsAg converting from positive to negative after initiation of SLGN, without any subsequent positive HBsAg result. The proportion of participants who achieved HBsAg loss after SLGN initiation and who sustained HBsAg loss during follow-up will be calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data.

Time frame:
From Baseline (Entry) through Week 48

Results for this outcome have not been posted.

SecondaryChanges From Baseline in qHBsAg Levels

The absolute change in qHBsAg level refers to the value at the follow-up time point minus the value at Baseline (Entry).

Time frame:
Baseline (Entry) and Weeks 4, 12, 24, 36 and 48

Results for this outcome have not been posted.

SecondaryProportion of Hepatitis B E-antigen (HBeAg) Positive Participants at Baseline Who Lose HBeAg at Any Time During the Study

HBeAg loss is defined as HBeAg changing from positive to negative. The proportion of participants who lose HBeAg at any time during the study will be calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data.

Time frame:
From Baseline (Entry) through Week 48

Results for this outcome have not been posted.

SecondaryProportion of Hepatitis B E-antibody (Anti-HBe) Negative Participants at Baseline Who Develop Anti-HBe at Any Time During the Study

Developing anti-HBe, or anti-HBe gain, is defined as HBeAb changing from negative to positive. The proportion of participants who develop HBeAb at any time during the study will be calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data.

Time frame:
From Baseline (Entry) through Week 48

Results for this outcome have not been posted.

SecondaryProportion of Hepatitis B Surface Antibody (Anti-HBs) Negative Participants at Baseline Who Develop Anti-HBs at Any Time During the Study

Developing anti-HBs, or anti-HBs gain, is defined as HBsAb changing from negative to positive. The proportion of participants who develop HBsAb at any time during the study will be calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data.

Time frame:
From Baseline (Entry) through Week 48

Results for this outcome have not been posted.

SecondaryNumber of Participants With Plasma HIV RNA >50 Copies/mL

The number of participants with detectable plasma HIV RNA \>50 copies/mL will be reported.

Time frame:
Weeks 2, 4, 24 and 48

Results for this outcome have not been posted.

SecondaryNumber of Participants With Serum HBV DNA >50 IU/mL

The number of participants with detectable serum HBV DNA \>50 copies/mL will be reported.

Time frame:
Weeks 2, 4, 24 and 48

Results for this outcome have not been posted.

Adverse events

Collected over From study entry to study completion at Week 48, or premature study discontinuation. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A0/22 (0%)3/22 (13.6%)16/22 (72.7%)
Arm B0/7 (0%)0/7 (0%)7/7 (100%)
Most frequent serious events
Most frequent serious events
EventArm AArm B
Pancreatitis acuteGastrointestinal disorders1/220/7
Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/220/7
Transient ischaemic attackNervous system disorders1/220/7
Most frequent other events
Showing 10 of 50
Most frequent other events
EventArm AArm B
Creatinine renal clearance decreasedInvestigations4/223/7
DiarrhoeaGastrointestinal disorders1/222/7
NauseaGastrointestinal disorders5/220/7
DyspepsiaGastrointestinal disorders0/221/7
GastritisGastrointestinal disorders0/221/7
InfluenzaInfections and infestations0/221/7
Parasitic gastroenteritisInfections and infestations0/221/7
Respiratory tract infection viralInfections and infestations0/221/7
Foot fractureInjury, poisoning and procedural complications0/221/7
Blood pressure increasedInvestigations0/221/7

Baseline characteristics

Age, Continuous
Age, Continuous(years)Arm AArm BTotal
Median48 (42 to 55)43 (40 to 53)46 (42 to 54)
Age, Customized
Age, Customized(Participants)Arm AArm BTotal
30-39 years516
40-49 years639
50-65 years11314
Sex: Female, Male
Sex: Female, Male(Participants)Arm AArm BTotal
Female213
Male20626
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm AArm BTotal
Hispanic or Latino314
Not Hispanic or Latino19625
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Arm AArm BTotal
American Indian or Alaska Native000
Asian12416
Native Hawaiian or Other Pacific Islander000
Black or African American426
White415
Other101
More than one race000
Unknown101
Region of Enrollment
Region of Enrollment(participants)Arm AArm BTotal
United States628
Brazil325
Thailand12315
Peru101
Hepatitis B DNA
Hepatitis B DNA(Participants)Arm AArm BTotal
<10 IU/mL19726
50+ IU/mL303
Hepatitis B Virus Surface Antigen
Hepatitis B Virus Surface Antigen(IU/mL)Arm AArm BTotal
Median1663 (1057 to 4169)1885 (1099 to 3620)1776 (1099 to 3620)

8 further baseline measures are reported on the registry.

08

Study locations

12 sites
  • UCSD Antiviral Research Center CRS (Site ID: 701)
    San Diego, California 92103, United States
  • The Ponce de Leon Center CRS (Site ID: 5802)
    Atlanta, Georgia 30308, United States
  • Weill Cornell Chelsea CRS (Site ID: 7804)
    New York, New York 10011, United States
  • Greensboro CRS (Site ID: 3203)
    Greensboro, North Carolina 27401, United States
  • Cincinnati Clinical Research Site (Site ID: 2401)
    Cincinnati, Ohio 45267-0405, United States
  • Case CRS (Site ID: 2501)
    Cleveland, Ohio 44106, United States
  • Univ of Pittsburgh (Site ID: 1001)
    Pittsburgh, Pennsylvania 15213, United States
  • Instituto de Pesquisas em AIDS do Rio Grande do Sul - IPARGS CRS (Site ID: 12201)
    Porto Alegre, Rio Grande do Sul 91350-180, Brazil
  • Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS (Site ID: 12101)
    Rio de Janeiro, 21040-360, Brazil
  • Barranco CRS (Site ID: 11301)
    Lima, 04, Peru
  • Thai Red Cross AIDS Research Centre (TRC-ARC) CRS (Site ID: 31802)
    Pathum Wan, Bangkok 10330, Thailand
  • Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS (Site ID: 31784)
    Chiang Mai, 50200, Thailand
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Individual participant data that underlie results in the publication, after deidentification

Supporting information: Study protocol, Statistical analysis plan

Time frame: Beginning 3 months following publication and available throughout period of funding of the Advancing Clinical Therapeutics Globally (ACTG) by NIH

Access criteria: With whom? Researchers who provide a methodologically sound proposal for use of the data that is approved by the ACTG. For what types of analyses? To achieve aims in the proposal approved by the ACTG. By what mechanism will data be made available? Researchers may submit a request for access to data using the ACTG "Data Request" form at: https://actgnetwork.org/submit-a-proposal/. Researchers of approved proposals will need to sign an ACTG Data Use Agreement before receiving the data.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2023 to primary completion in Oct 2025, 29 months.

Results were first posted in Nov 2026, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2022
First posted
Sep 22, 2022
StartActual
May 1, 2023
Primary completionActual
Oct 29, 2025
CompletionActual
Apr 8, 2026
Results first posted
Nov 17, 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Completed→Terminated ACTG Network funding disruptions
changed Nov 17, 2026
Results
Results posted
posted Nov 17, 2026
Sites
12 sites added, 12 sites removed
Show 12 added (7 United States, 2 Brazil, 2 Thailand, 1 Peru)
  • UCSD Antiviral Research Center CRS (Site ID: 701) · San Diego, United States
  • The Ponce de Leon Center CRS (Site ID: 5802) · Atlanta, United States
  • Weill Cornell Chelsea CRS (Site ID: 7804) · New York, United States
  • Greensboro CRS (Site ID: 3203) · Greensboro, United States
  • Cincinnati Clinical Research Site (Site ID: 2401) · Cincinnati, United States
  • Case CRS (Site ID: 2501) · Cleveland, United States
  • Univ of Pittsburgh (Site ID: 1001) · Pittsburgh, United States
  • Instituto de Pesquisas em AIDS do Rio Grande do Sul - IPARGS CRS (Site ID: 12201) · Porto Alegre, Brazil
  • Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS (Site ID: 12101) · Rio de Janeiro, Brazil
  • Barranco CRS (Site ID: 11301) · Lima, Peru
  • Thai Red Cross AIDS Research Centre (TRC-ARC) CRS (Site ID: 31802) · Pathum Wan, Thailand
  • Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS (Site ID: 31784) · Chiang Mai, Thailand
Show 12 removed
  • UCSD Antiviral Research Center CRS (Site 701) · San Diego, United States
  • The Ponce de Leon Center CRS (Site 5802) · Atlanta, United States
  • Weill Cornell Chelsea CRS (Site 7804) · New York, United States
  • Greensboro CRS (Site# 3203) · Greensboro, United States
  • Cincinnati Clinical Research Site (Site 2401) · Cincinnati, United States
  • Case CRS (Site ID# 2501) · Cleveland, United States
  • Univ of Pittsburgh (Site 1001) · Pittsburgh, United States
  • Instituto de Pesquisas em AIDS do Rio Grande do Sul - IPARGS CRS (Site 12201) · Porto Alegre, Brazil
  • Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS (Site ID# 12101) · Rio de Janeiro, Brazil
  • Barranco CRS (Site 11301) · Lima, Peru
  • Thai Red Cross AIDS Research Centre (TRC-ARC) CRS (Site 31802) · Pathum Wan, Thailand
  • Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS (Site 31784) · Chiang Mai, Thailand
Nov 17, 2026
Start date
May 5, 2023→May 1, 2023
Nov 17, 2026
Eligibility
1 inclusion criterion removed
What changed in the criteria
Inclusion criteria
  • RemovedParticipants age ≥18 years and ≤70 years at study entry
Nov 17, 2026
Primary outcomes
3 edited
What changed in the outcomes
  • EditedProportion of participants who experienced adverse eventsParticipants Who Experienced Grade ≥2 Adverse Events (AEs) in Arm ATime frame: From study treatment initiation to Week 24 → From study treatment initiation through Week 24
  • EditedProportion of participants who prematurely discontinued treatment dueParticipants Who Prematurely Discontinued Treatment Due to adverse eventsAdverse Events (AEs) in Arm ATime frame: From study treatment initiation to Week 24 → From study treatment initiation through Week 24
  • EditedProportion of participants withParticipants With ≥1 log10 IU/mL decline from baselineDecline From Baseline in quantitativeQuantitative HBsAg (qHBsAg) afterAfter SLGN treatmentTreatment at Week 24Time frame: At week 24 → Week 24
Nov 17, 2026
Secondary outcomes
10 edited
What changed in the outcomes
  • EditedProportion of participants withParticipants With ≥1 log10 IU/mL decline from baselineDecline From Baseline in qHBsAg at any time duringAny Time During the study afterStudy After SLGN treatmentTreatment InitiationTime frame: Baseline though week 48 → From Baseline (Entry) through Week 48
  • EditedProportion of participants withParticipants With ≥0.5 log10 IU/mL decline from baselineDecline From Baseline in qHBsAg afterAfter SLGN treatmentTreatment at Week 24Time frame: At week 24 → Week 24
  • EditedProportion of participants withParticipants With ≥0.5 log10 IU/mL declineDecline in qHBsAg from baselineFrom Baseline at any time duringAny Time During the study afterStudy After SLGN treatment initiationTreatment InitiationTime frame: Baseline though week 48 → From Baseline (Entry) through Week 48
  • EditedProportion of participants who achieveParticipants Who Achieve HBsAg loss afterLoss After SLGN initiationInitiation and who sustainWho Sustain HBsAg loss during followLoss During Follow-upTime frame: Baseline though week 48 → From Baseline (Entry) through Week 48
  • EditedChanges from baselineFrom Baseline in qHBsAg levels at Weeks 4, 12, 24, 36, and 48LevelsTime frame: At week 4, 12, 24, 36 and 48 → Baseline (Entry) and Weeks 4, 12, 24, 36 and 48
  • EditedProportion of Hepatitis B E-antigen (HBeAg positive participants) Positive Participants at baseline who loseBaseline Who Lose HBeAg at any time duringAny Time During the studyStudyTime frame: Baseline though week 48 → From Baseline (Entry) through Week 48
  • EditedProportion of antiHepatitis B E-antibody (Anti-HBe negative participants) Negative Participants at baseline who develop antiBaseline Who Develop Anti-HBe at any time duringAny Time During the studyStudyTime frame: Baseline though week 48 → From Baseline (Entry) through Week 48
  • EditedProportion of hepatitisHepatitis B surface antibodySurface Antibody (antiAnti-HBs) negative participantsNegative Participants at baseline who develop antiBaseline Who Develop Anti-HBs at any time duringAny Time During the studyStudyTime frame: Baseline though week 48 → From Baseline (Entry) through Week 48
  • EditedDetectionNumber of plasmaParticipants With Plasma HIV RNA >50 copiesCopies/mL at weeks 2, 4, 24, and 48Time frame: At Weeks 2, 4, 24 and 48 → Weeks 2, 4, 24 and 48
  • EditedDetectionNumber of serumParticipants With Serum HBV DNA >50 IU/mL at weeks 2, 4, 24, and 48Time frame: At Weeks 2, 4, 24 and 48 → Weeks 2, 4, 24 and 48
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Completed→Terminated
    Why stopped ACTG Network funding disruptions
    Results posted
    12 sites added, 12 sites removed
    Show 12 added (7 United States, 2 Brazil, 2 Thailand, 1 Peru)
    • UCSD Antiviral Research Center CRS (Site ID: 701) · San Diego, United States
    • The Ponce de Leon Center CRS (Site ID: 5802) · Atlanta, United States
    • Weill Cornell Chelsea CRS (Site ID: 7804) · New York, United States
    • Greensboro CRS (Site ID: 3203) · Greensboro, United States
    • Cincinnati Clinical Research Site (Site ID: 2401) · Cincinnati, United States
    • Case CRS (Site ID: 2501) · Cleveland, United States
    • Univ of Pittsburgh (Site ID: 1001) · Pittsburgh, United States
    • Instituto de Pesquisas em AIDS do Rio Grande do Sul - IPARGS CRS (Site ID: 12201) · Porto Alegre, Brazil
    • Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS (Site ID: 12101) · Rio de Janeiro, Brazil
    • Barranco CRS (Site ID: 11301) · Lima, Peru
    • Thai Red Cross AIDS Research Centre (TRC-ARC) CRS (Site ID: 31802) · Pathum Wan, Thailand
    • Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS (Site ID: 31784) · Chiang Mai, Thailand
    Show 12 removed
    • UCSD Antiviral Research Center CRS (Site 701) · San Diego, United States
    • The Ponce de Leon Center CRS (Site 5802) · Atlanta, United States
    • Weill Cornell Chelsea CRS (Site 7804) · New York, United States
    • Greensboro CRS (Site# 3203) · Greensboro, United States
    • Cincinnati Clinical Research Site (Site 2401) · Cincinnati, United States
    • Case CRS (Site ID# 2501) · Cleveland, United States
    • Univ of Pittsburgh (Site 1001) · Pittsburgh, United States
    • Instituto de Pesquisas em AIDS do Rio Grande do Sul - IPARGS CRS (Site 12201) · Porto Alegre, Brazil
    • Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS (Site ID# 12101) · Rio de Janeiro, Brazil
    • Barranco CRS (Site 11301) · Lima, Peru
    • Thai Red Cross AIDS Research Centre (TRC-ARC) CRS (Site 31802) · Pathum Wan, Thailand
    • Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS (Site 31784) · Chiang Mai, Thailand
    Start date May 5, 2023→May 1, 2023
    Eligibility 1 inclusion criterion removed
    What changed in the criteria
    Inclusion criteria
    • RemovedParticipants age ≥18 years and ≤70 years at study entry
    Primary outcomes 3 edited
    What changed in the outcomes
    • EditedProportion of participants who experienced adverse eventsParticipants Who Experienced Grade ≥2 Adverse Events (AEs) in Arm ATime frame: From study treatment initiation to Week 24 → From study treatment initiation through Week 24
    • EditedProportion of participants who prematurely discontinued treatment dueParticipants Who Prematurely Discontinued Treatment Due to adverse eventsAdverse Events (AEs) in Arm ATime frame: From study treatment initiation to Week 24 → From study treatment initiation through Week 24
    • EditedProportion of participants withParticipants With ≥1 log10 IU/mL decline from baselineDecline From Baseline in quantitativeQuantitative HBsAg (qHBsAg) afterAfter SLGN treatmentTreatment at Week 24Time frame: At week 24 → Week 24
    Secondary outcomes 10 edited
    What changed in the outcomes
    • EditedProportion of participants withParticipants With ≥1 log10 IU/mL decline from baselineDecline From Baseline in qHBsAg at any time duringAny Time During the study afterStudy After SLGN treatmentTreatment InitiationTime frame: Baseline though week 48 → From Baseline (Entry) through Week 48
    • EditedProportion of participants withParticipants With ≥0.5 log10 IU/mL decline from baselineDecline From Baseline in qHBsAg afterAfter SLGN treatmentTreatment at Week 24Time frame: At week 24 → Week 24
    • EditedProportion of participants withParticipants With ≥0.5 log10 IU/mL declineDecline in qHBsAg from baselineFrom Baseline at any time duringAny Time During the study afterStudy After SLGN treatment initiationTreatment InitiationTime frame: Baseline though week 48 → From Baseline (Entry) through Week 48
    • EditedProportion of participants who achieveParticipants Who Achieve HBsAg loss afterLoss After SLGN initiationInitiation and who sustainWho Sustain HBsAg loss during followLoss During Follow-upTime frame: Baseline though week 48 → From Baseline (Entry) through Week 48
    • EditedChanges from baselineFrom Baseline in qHBsAg levels at Weeks 4, 12, 24, 36, and 48LevelsTime frame: At week 4, 12, 24, 36 and 48 → Baseline (Entry) and Weeks 4, 12, 24, 36 and 48
    • EditedProportion of Hepatitis B E-antigen (HBeAg positive participants) Positive Participants at baseline who loseBaseline Who Lose HBeAg at any time duringAny Time During the studyStudyTime frame: Baseline though week 48 → From Baseline (Entry) through Week 48
    • EditedProportion of antiHepatitis B E-antibody (Anti-HBe negative participants) Negative Participants at baseline who develop antiBaseline Who Develop Anti-HBe at any time duringAny Time During the studyStudyTime frame: Baseline though week 48 → From Baseline (Entry) through Week 48
    • EditedProportion of hepatitisHepatitis B surface antibodySurface Antibody (antiAnti-HBs) negative participantsNegative Participants at baseline who develop antiBaseline Who Develop Anti-HBs at any time duringAny Time During the studyStudyTime frame: Baseline though week 48 → From Baseline (Entry) through Week 48
    • EditedDetectionNumber of plasmaParticipants With Plasma HIV RNA >50 copiesCopies/mL at weeks 2, 4, 24, and 48Time frame: At Weeks 2, 4, 24 and 48 → Weeks 2, 4, 24 and 48
    • EditedDetectionNumber of serumParticipants With Serum HBV DNA >50 IU/mL at weeks 2, 4, 24, and 48Time frame: At Weeks 2, 4, 24 and 48 → Weeks 2, 4, 24 and 48
    + 7 other changes: verification date, responsible party, oversight details, description, arm descriptions, data sharing statement and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05551273
Collaborators
Gilead Sciences
Responsible party
Sponsor
First posted
Sep 22, 2022
Start date
May 1, 2023
Primary completion
Oct 29, 2025
Completion
Apr 8, 2026
Results posted
Nov 17, 2026
Last update
Nov 17, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selgantolimod

Start the discussion